IMMUCYST 81 MG
BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG · DIN 02194376 · SANOFI PASTEUR LIMITED
Health Canada status: CANCELLED POST MARKET
What is IMMUCYST?
IMMUCYST 81 MG contains BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG. It is listed in the Health Canada Drug Product Database under DIN 02194376, held by SANOFI PASTEUR LIMITED, supplied as POWDER FOR SUSPENSION for INTRAVESICAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMMUCYST used for?
Treatment/prophylaxis of carcinoma in situ (CIS) of the urinary bladder and prophylaxis of stage Ta and/or T1 papillary tumours following transurethral resection (TUR).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02194376 |
|---|---|
| Brand name | IMMUCYST |
| Generic / active ingredient | BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 81 MG |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | INTRAVESICAL |
| Schedule | Prescription |
| ATC code | L03AX03 BCG VACCINE |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jan-2018 |
| Original market date | 1990-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02194376 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2194376 |
| Brand name | IMMUCYST |
| Active ingredient / INN | BACILLUS CALMETTE-GUERIN (BCG) SUBSTRAIN CONNAUGHT : 81 MG |
| ATC code | L03AX03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03 |
| AHFS class | 80:12.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SANOFI PASTEUR LIMITED |
How is it administered?
Intravesical instillation only. Reconstituted 81 mg dose retained in bladder for up to 2 hours. Induction and maintenance schedules used. Do not inject SC, ID, or IV.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (refer to "HOW TO STORE IT" section 23 which is not fully detailed in the snippet).
How is it supplied?
Not explicitly detailed in text beyond "vial" with a natural latex rubber stopper.
Which pack is which?
| Strength on the label | 81 MG |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | INTRAVESICAL |
| Packaging as described in the monograph | Not explicitly detailed in text beyond "vial" with a natural latex rubber stopper. |
| Storage | Not specified in the provided text (refer to "HOW TO STORE IT" section 23 which is not fully detailed in the snippet). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; active tuberculosis; history of systemic BCG reaction; febrile illness, UTI, or gross hematuria; immune deficiencies; within 14 days of biopsy, TUR, or traumatic catheterization.
Warnings and precautions
Serious systemic BCG reactions (may be fatal); handle as infectious; risk of ectopic infection in patients with prosthetic devices; avoid trauma to urinary tract.
What can be used instead?
Other Canadian products sharing ATC code L03AX03 BCG VACCINE. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ONCOTICE | 800000000 UNIT | POWDER FOR SOLUTION | MERCK CANADA INC | MARKETED | DIN 02153513 |
| VERITY-BCG | 40 MG | POWDER FOR SUSPENSION | VERITY PHARMACEUTICALS INC. | MARKETED | DIN 02508613 |
| BCG THERAPEUTIC | 27 MG | POWDER FOR SOLUTION | CONNAUGHT LABORATORIES LTD. | CANCELLED POST MARKET | DIN 00884308 |
| PACIS | 120 MG | POWDER FOR SOLUTION | ID BIOMEDICAL CORPORATION OF QUEBEC | CANCELLED POST MARKET | DIN 02130947 |
Who else supplies BCG VACCINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BCG VACCINE appears in 12 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.